Section Arrow
Quote
NEUP.NASDAQ
- Neuphoria Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/21 06:43 EDT
Pre Market
Last
 7.45
0 (0.00%)
Bid
7.68
Ask
9.41
High 7.45 
Low 7.45 
Volume 30 
Regular Hours
Last
 7.45
-0.04 (-0.53%)
Day High 
7.5622 
Prev. Close
7.49 
1-M High
7.7924 
Volume 
12.93K 
Bid
7.68
Ask
9.41
Day Low
7.45 
Open
7.46 
1-M Low
5.99 
Market Cap 
14.08M 
Currency USD 
P/E 0.4 
%Yield -- 
10-SMA 7.44 
20-SMA 7.1 
50-SMA 6.5 
52-W High 12.55 
52-W Low 2.123988 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
18.83/-1.88
Enterprise Value
14.20M
Balance Sheet
Book Value Per Share
13.83
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
181.36K
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.13 -0.945 -6.71%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0475 -0.0002 -0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.